Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV003747283 | SCV004433391 | uncertain significance | Tumor predisposition syndrome 3 | 2023-05-08 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt POT1 protein function. This variant has not been reported in the literature in individuals affected with POT1-related conditions. This variant is present in population databases (rs751455733, gnomAD 0.0009%). This sequence change replaces arginine, which is basic and polar, with serine, which is neutral and polar, at codon 477 of the POT1 protein (p.Arg477Ser). |
Ambry Genetics | RCV004654285 | SCV005150663 | uncertain significance | Hereditary cancer-predisposing syndrome | 2024-04-08 | criteria provided, single submitter | clinical testing | The p.R477S variant (also known as c.1431A>T), located in coding exon 11 of the POT1 gene, results from an A to T substitution at nucleotide position 1431. The arginine at codon 477 is replaced by serine, an amino acid with dissimilar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Based on the available evidence, the clinical significance of this variant remains unclear. |